Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Financials
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Is AstraZeneca stretching too thin with M&As? CEO says 'no'
Apr 25, 2024 11:09am
Merck touts newly approved Winrevair as example of BD acumen
Apr 25, 2024 11:06am
Novartis gears up for key expansions of 3 cancer drugs
Apr 23, 2024 3:37pm
Novartis nominates ex-BMS chief Caforio as its next chair
Apr 23, 2024 2:44am
Amgen CEO nabs pay raise thanks to Horizon deal
Apr 18, 2024 5:08pm